Free Trial

Acutus Medical (AFIB) Stock Price, News & Analysis

-0.01 (-13.64%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
50-Day Range
52-Week Range
118,600 shs
Average Volume
1.71 million shs
Market Capitalization
$1.36 million
P/E Ratio
Dividend Yield
Price Target
AFIB stock logo

About Acutus Medical Stock (NASDAQ:AFIB)

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.

AFIB Stock Price History

AFIB Stock News Headlines

AI Might Boost Detection of A-Fib
Acutus Medical Inc (AFIB)
See More Headlines
Receive AFIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acutus Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$7.16 million
Book Value
($0.14) per share


Free Float
Market Cap
$1.36 million

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Takeo Mukai (Age 43)
    CEO & CFO
    Comp: $385.01k
  • Mr. Gary W. Doherty B.S. (Age 57)
    Senior Vice President of Finance
    Comp: $434.32k

AFIB Stock Analysis - Frequently Asked Questions

How have AFIB shares performed in 2024?

Acutus Medical's stock was trading at $0.2019 at the beginning of 2024. Since then, AFIB stock has decreased by 77.4% and is now trading at $0.0456.
View the best growth stocks for 2024 here

How were Acutus Medical's earnings last quarter?

Acutus Medical, Inc. (NASDAQ:AFIB) released its earnings results on Thursday, May, 9th. The company reported ($0.07) EPS for the quarter. The firm had revenue of $3.63 million for the quarter. Acutus Medical had a negative net margin of 166.79% and a negative trailing twelve-month return on equity of 54.97%.

What other stocks do shareholders of Acutus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acutus Medical investors own include Oak Street Health (OSH), Alibaba Group (BABA), Checkmate Pharmaceuticals (CMPI), Salesforce (CRM), Walt Disney (DIS), DocuSign (DOCU), Marvell Technology (MRVL), NVIDIA (NVDA), Tesla (TSLA) and Twilio (TWLO).

When did Acutus Medical IPO?

Acutus Medical (AFIB) raised $126 million in an initial public offering on Thursday, August 6th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, BofA Securities and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Who are Acutus Medical's major shareholders?

Acutus Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James F Hinrichs, Orbimed Advisors Llc and R Scott Huennekens.
View institutional ownership trends

How do I buy shares of Acutus Medical?

Shares of AFIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Acutus Medical have any subsidiaries?
The following companies are subsidiares of Acutus Medical: Acutus Medical N.V..
Read More
This page (NASDAQ:AFIB) was last updated on 5/27/2024 by Staff

From Our Partners